Accès ouvert
2026
article
OpenAlex
Wei-Yu Chen, Kuan‐Hua Huang, Gagan Kajla, Yu-Ching Wen et autres
Neuroendocrine prostate cancer (NEPC) is a lethal, treatment-resistant subtype that arises through lineage transdifferentiation from castration-resistant prostate cancer (CRPC) under selective pressure from androgen deprivation therapy. Although EGFR tyrosine kinase inhibitors (TKIs) represent a rational therapeutic strategy, their clinical efficacy remains limited, …
tw, us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Phan Vu Thuy Dung, Wei‐Yu Chen, Mingkun Liu, Shauh-Der Yeh et autres
Neuroendocrine prostate cancer (NEPC) represents a highly aggressive, treatment‑refractory phenotype that frequently emerges after androgen‑deprivation therapy (ADT). Although perturbed calcium signaling has been implicated in prostate cancer bone metastasis, the specific molecular mechanisms governing NEPC progression remain incompletely characterized. Here, we delineate …
tw, us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Ke Hung Tsui, Chien‐Liang Liu, Hsiu-Lien Yeh, Mingkun Liu et autres
The interaction between prostate cancer (PCa) cells and prostate stromal cells fosters an immunosuppressive tumor microenvironment (TME) that promotes tumor growth and immune evasion. However, the specific signaling pathways involved remain unclear. We identified a key mechanism involving the CXCL5/CXCR2 and LIF/LIFR …
tw, lb
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Yen‐Nien Liu, Mingkun Liu, Yu-Ching Wen, Chien‐Hsiu Li et autres
The tumor microenvironment (TME) of prostate cancer (PCa) is characterized by high levels of immunosuppressive molecules, including cytokines and chemokines. This creates a hostile immune landscape that impedes effective immune responses. The interleukin-1 (IL-1) receptor antagonist (IL1RN), a key anti-inflammatory molecule, plays …
tw, us
(code pays fourni par la source)
2024
article
OpenAlex
Yen‐Nien Liu, Wei‐Yu Chen, Hsiu‐Lien Yeh, Wei-Hao Chen et autres
Neuroendocrine prostate cancer (PCa) (NEPC), an aggressive subtype that is associated with poor prognosis, may arise after androgen deprivation therapy (ADT). We investigated the molecular mechanisms by which ADT induces neuroendocrine differentiation in advanced PCa. We found that transmembrane protein 1 (MCTP1), …
tw, us
(code pays fourni par la source)
Accès ouvert
2024
erratum
OpenAlex
Yu‐Ching Wen, Van Thi Ngoc Tram, Weihao Chen, Chien‐Hsiu Li et autres
5 Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
tw, us
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Van Thi Ngoc Tram, Hoang Dang Khoa Ta, Gangga Anuraga, Phan Vu Thuy Dung et autres
Prostate cancer (PCa) is one of the most prevalent cancers in men, yet its pathogenic pathways remain poorly understood. Transcriptomics and high-throughput sequencing can help uncover cancer diagnostic targets and understand biological circuits. Using prostate adenocarcinoma (PRAD) datasets of various web-based applications …
vn, tw, id
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Yu‐Ching Wen, Van Thi Ngoc Tram, Weihao Chen, Chien‐Hsiu Li et autres
Current treatment options for prostate cancer focus on targeting androgen receptor (AR) signaling. Inhibiting effects of AR may activate neuroendocrine differentiation and lineage plasticity pathways, thereby promoting the development of neuroendocrine prostate cancer (NEPC). Understanding the regulatory mechanisms of AR has important …
tw, us
(code pays fourni par la source)
2023
conference-abstract
OpenAlex
Yen‐Nien Liu, Wei‐Yu Chen, Phan Vu Thuy Dung, Hsiu‐Lien Yeh et autres
Abstract Conventional treatment of prostate cancer (PCa) uses androgen deprivation therapy (ADT) to inhibit androgen receptor (AR) signaling-driven tumor progression. ADT-induced PCa recurrence may progress to AR-negative phenotype with neuroendocrine (NE) features on histology, which is associated with metabolic disturbances and poor …
tw
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Wei‐Yu Chen, Phan Vu Thuy Dung, Hsiu‐Lien Yeh, Weihao Chen et autres
Conventional treatment of prostate cancer (PCa) uses androgen-deprivation therapy (ADT) to inhibit androgen receptor (AR) signaling-driven tumor progression. ADT-induced PCa recurrence may progress to an AR-negative phenotype with neuroendocrine (NE) histologic features, which are associated with metabolic disturbances and poor prognoses. However, …
tw, us
(code pays fourni par la source)
Accès ouvert
2022
preprint
OpenAlex
Yen‐Nien Liu, Wei‐Yu Chen, Hsiu‐Lien Yeh, Weihao Chen et autres
Abstract Background Prostate cancer (PCa) patients with bone metastases frequently exhibit abnormal calcium homeostasis. However, the molecular mechanisms underlying bone metastasis mediated by activated calcium transport signaling remain unclear. Our results showed that androgen deprivation therapy (ADT) of PCa upregulates a calcium …
tw, us
(code pays fourni par la source)